KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Nektar Therapeutics (NKTR) Accumulated Depreciation & Amortization: 2018-2022

  • Nektar Therapeutics' Accumulated Depreciation & Amortization was N/A to $132.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $414.7 million, marking a year-over-year change of. This contributed to the annual value of $4.1 million for FY2024, which is 41.43% down from last year.
  • Per Nektar Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $132.8 million for Q3 2022, which was down 4.83% from $139.6 million recorded in Q2 2022.
  • In the past 5 years, Nektar Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $140.9 million in Q4 2021 and a low of $1.0 million during Q4 2018.
  • For the 2-year period, Nektar Therapeutics' Accumulated Depreciation & Amortization averaged around $137.7 million, with its median value being $139.6 million (2022).
  • Data for Nektar Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY surged of 41.66% (in 2019) over the last 5 years.
  • Quarterly analysis of 4 years shows Nektar Therapeutics' Accumulated Depreciation & Amortization stood at $1.0 million in 2018, then soared by 41.66% to $1.4 million in 2019, then reached $140.9 million in 2021, then reached $132.8 million in 2022.
  • Its last three reported values are $132.8 million in Q3 2022, $139.6 million for Q2 2022, and $140.9 million during Q4 2021.